| 1 |
Sun YQ, He GL, Chang YJ, et al. The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation[J]. Ann Hematol, 2015, 94(10)：1699-1705.
|
| 2 |
Larocca A, Piaggio G, Podestà M, et al. Boost of CD34＋-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation[J]. Haematologica, 2006, 91(7)：935-940.
|
| 3 |
Lee KH, Lee JH, Choi SJ, et al. Failure of trilineage blood cell reconstitution after initial neutrophil engraftment in patients undergoing allogeneic hematopoietic cell transplantation – frequency and outcomes[J]. Bone Marrow Transplant, 2004, 33(7)：729-734.
|
| 4 |
Zhao Y, Gao F, Shi J, et al. Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation-ScienceDirect[J]. Biol Blood Marrow Transplant, 2019, 25(9)：1898-1907.
|
| 5 |
Zhang R, He Y, Yang D, et al. Combination treatment of rituximab and donor platelets infusion to reduce donor-specific anti-HLA antibodies for stem cells engraftment in haploidentical transplantation[J]. J Clin Lab Anal, 2020, 34(7)：e23261.
|
| 6 |
Yang X, Song J, Jiang Z, et al. Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation[J]. Int J Med Sci, 2014, 11(6)：652-657.
|
| 7 |
Peralvo J, Bacigalupo A, Pittaluga PA, et al. Poor graft function associated with graft-versus-host disease after allogeneic marrow transplantation[J]. Bone Marrow Transplant, 1987, 2(3)：279-285.
|
| 8 |
Zhang Y, Zhai W, Zhao M, et al. Effects of iron overload on the bone marrow microenvironment in mice[J]. PloS One, 2015, 10(3): e0120219.
|
| 9 |
Jin X, He X, Cao X, et al. Iron overload impairs normal hematopoietic stem and progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice[J]. Haematologica, 2018, 103(10)：1627-1634.
|
| 10 |
Gu S, Zhao Y, Guo J, et al. High expression of APAF-1 elevates erythroid apoptosis in iron overload myelodysplastic syndrome[J]. Tumour Biol, 2014, 35(3)：2211-2218.
|
| 11 |
Sucak GT, Yegin ZA, Ozkurt ZN, et al. Iron overload: predictor of adverse outcome in hematopoietic stem cell transplantation[J]. Transplant Proc, 2010, 42(5)：1841-1848.
|
| 12 |
Lee JW, Kang HJ, Kim EK, et al. Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children[J]. Bone Marrow Transplant, 2009, 44(12)：793.
|
| 13 |
Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias[J]. Haematologica, 2010, 95(4): 557-566.
|
| 14 |
Wu D, Wen X, Liu W, et al. Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload[J]. Drug Des Devel Ther, 2018, 12：1081-1091.
|
| 15 |
Cheong JW, Kim HJ, Lee KH, et al. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia[J]. Transfusion, 2014, 54(6)：1542.
|